Back to Search Start Over

Myocarditis Following COVID-19 Vaccination.

Authors :
Marschner CA
Shaw KE
Tijmes FS
Fronza M
Khullar S
Seidman MA
Thavendiranathan P
Udell JA
Wald RM
Hanneman K
Source :
Heart failure clinics [Heart Fail Clin] 2023 Apr; Vol. 19 (2), pp. 251-264.
Publication Year :
2023

Abstract

Myocarditis is an established but rare adverse event following administration of messenger RNA-based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings, and proposed pathophysiologic mechanisms.<br />Competing Interests: Disclosure Dr K. Hanneman has received speaker’s honorarium from Sanofi-Genzyme, Amicus, and Medscape. Dr P. Thavendiranathan has received speaker’s honorarium from Amgen, Boehringer Ingelheim-Lilly, and Takeda. Dr J.A. Udell has served as a consultant or speaker for AstraZeneca, Bayer, Boehringer Ingelheim-Lilly, Janssen, Merck, Novartis, and Sanofi and has received research grants from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim-Lilly, and Janssen.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1551-7136
Volume :
19
Issue :
2
Database :
MEDLINE
Journal :
Heart failure clinics
Publication Type :
Academic Journal
Accession number :
36863817
Full Text :
https://doi.org/10.1016/j.hfc.2022.08.012